Investigation of the Serotonin, Cortisol Hormones and some Biochemical Parameters in Patients with Beta Thalassemia in Thi-Qar Governorate /Iraq
DOI:
https://doi.org/10.32792/utq/utjsci/v11i1.1186Abstract
Beta thalassemia (β-thalassemia) is the most severe kind of β-thalassemia hereditary disease that makes blood transfusion dependent. Patients with β-thalassemia disease experience many physiological abnormalities, including oxidative stress, iron overload, and aggregated β-globin proteins. These abnormalities may also lead to premature RBC mortality. In the present study, 100 patients with β-thalassemia major with an average age of 16.30 ± 6.67 years old and 30 healthy controls with an average age of 14.63 ± 4.17 years old were included in this study. The serum levels of urea, creatinine, serotonin, and cortisol were investigated in the patient and control groups. The results showed a marked increase in the urea levels among the patients compared to the control group (from 14.63 ± 6.05 mg/dl in the control group to 24.98 ± 11.35 mg/dl in patient group) with P <0.001, rendering this change highly statistically significant. While there was a noticeable increase in creatinine levels between patients and controls (from 0.387 ± 0.199 mg/dl in the control group to 0.466 ± 0.208 mg/dl in the patient group. Statistical analysis revealed this change with non-significance of P = 0.066. Furthermore, the obtained results indicated that the serum level of serotonin decreased in patient group (from 393.46 ± 192.42 ng/ml in control group to 385.63 ± 167.70 ng/ml in patient group) with P=0.884, while β-thalassemia major subjects showed a significantly higher level of cortisol compared to the healthy control group (from 94.97 ± 67.56 ng/ml in control group
Received: 2024-03-04
Revised: 2024-03-23
Accepted: 2024-03-30
References
D. Rund and E. Rachmilewitz, "β-Thalassemia," New England Journal of Medicine, vol. 353, no. 11, pp. 1135-1146, 2005.
M. H. Steinberg, B. G. Forget, D. R. Higgs, and D. J. Weatherall, Disorders of hemoglobin: genetics, pathophysiology, and clinical management. Cambridge University Press, 2009.
A. Kattamis, G. L. Forni, Y. Aydinok, and V. Viprakasit, "Changing patterns in the epidemiology of β‐thalassemia," European Journal of Haematology, vol. 105, no. 6, pp. 692-703, 2020.
F. B. Piel and D. J. Weatherall, "The α-thalassemias," New England Journal of Medicine, vol. 371, no. 20, pp. 1908-1916, 2014.
E. Khandros, C. S. Thom, J. D'Souza, and M. J. Weiss, "Integrated protein quality-control pathways regulate free α-globin in murine β-thalassemia," Blood, The Journal of the American Society of Hematology, vol. 119, no. 22, pp. 5265-5275, 2012.
A. Premawardhena et al., "A novel molecular basis for β thalassemia intermedia poses new questions about its pathophysiology," Blood, vol. 106, no. 9, pp. 3251-3255, 2005.
A. Basak et al., "Control of human hemoglobin switching by LIN28B-mediated regulation of BCL11A translation," NatureGeneticss, vol. 52, no. 2, pp. 138-145, 2020.
M. Uda et al., "Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of β-thalassemia," Proceedings of the National Academy of Sciences, vol. 105, no. 5, pp. 1620-1625, 2008.
C. Hershko, "Pathogenesis and management of iron toxicity in thalassemia," Annals of the New York Academy of Sciences, vol. 1202, no. 1, pp. 1-9, 2010.
F. Centis et al., "The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with β-thalassemia major," Blood, The Journal of the American Society of Hematology, vol. 96, no. 10, pp. 3624-3629, 2000.
J. Yuan et al., "Accelerated programmed cell death (apoptosis) in erythroid," 2011.
P. Pootrakul et al., "A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in Thai patients with thalassemia: Presented in part at the XXI Congress of the International Society of Hematology, Sydney, Australia, May 1985, and the Annual Meeting of the American Society of Hematology, San Diego, CA, December 1997," Blood, The Journal of the American Society of Hematology, vol. 96, no. 7, pp. 2606-2612, 2000.
D. Mandal et al., "Caspase 3-mediated proteolysis of the N-terminal cytoplasmic domain of the human erythroid anion exchanger 1 (band 3)," Journal of Biological Chemistry, vol. 278, no. 52, pp. 52551-52558, 2003.
S. Ficarra et al., "Derangement of erythrocytic AE1 in beta-thalassemia by caspase 3: pathogenic mechanisms and implications in red blood cell senescence," Journal of Membrane Biology, vol. 228, pp. 43-49, 2009.
A. A. Mahmoud et al., "Assessment of subclinical renal glomerular and tubular dysfunction in children with beta-thalassemia major," Children, vol. 8, no. 2, p. 100, 2021.
M. G. Shaalan, M. K. Hassan, H. J. Al-Shanoof, and L. M. Al Naama, "Renal dysfunction in pediatric patients in Iraq with β-thalassemia major and intermedia," Cureus, vol. 14, no. 9, 2022.
M. Mohkam, B. S. Shamsian, A. Gharib, S. Nariman, and M. T. Arzanian, "Early markers of renal dysfunction in patients with beta-thalassemia major," Pediatric nephrology, vol. 23, pp. 971-976, 2008.
A. Kassab-Chekir et al., "Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia," Clinica Chimica Acta, vol. 338, no. 1-2, pp. 79-86, 2003.
V. Sen et al., "Urinary early kidney injury molecules in children with beta-thalassemia major," Renal failure, vol. 37, no. 4, pp. 607-613, 2015.
A. N. Saliba et al., "Thalassemia in the emergency department: special considerations for a rare disease," Annals of Hematology, vol. 99, pp. 1967-1977, 2020.
M. M. Islam et al., "Distribution of β-thalassemia and other hemoglobinopathies in Bangladeshi university students and ready-made garment workers," Risk Management and Healthcare Policy, pp. 2707-2714, 2021.
P. Pasqualetti, D. Colantonio, A. Collacciani, R. Casale, and G. Natali, "Circadian pattern of circulating plasma ACTH, cortisol, and aldosterone in patients with β-thalassemia," European Journal of Endocrinology, vol. 123, no. 2, pp. 174-178, 1990.
P. Ott, "Membrane acetylcholinesterases: purification, molecular properties and interactions with amphiphilic environments," Biochimica et Biophysica Acta (BBA)-Reviews on Biomembranes, vol. 822, no. 3-4, pp. 375-392, 1985.
L. Khodadadi, Q. Cheng, A. Radbruch, and F. Hiepe, "The maintenance of memory plasma cells," Frontiers in immunology, p. 721, 2019.
K. Hofmann, A.-K. Clauder, and R. A. Manz, "Targeting B cells and plasma cells in autoimmune diseases," Frontiers in Immunology, vol. 9, p. 835, 2018.
R. Leo et al., "Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells," Annals of hematology, vol. 64, pp. 132-139, 1992.
S. Z. Usmani et al., "Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma," Blood, The Journal of the American Society of Hematology, vol. 128, no. 1, pp. 37-44, 2016.
M. A. Dimopoulos et al., "Daratumumab, lenalidomide, and dexamethasone for multiple myeloma," New England Journal of Medicine, vol. 375, no. 14, pp. 1319-1331, 2016.
A. Palumbo et al., "Daratumumab, bortezomib, and dexamethasone for multiple myeloma," New England Journal of Medicine, vol. 375, no. 8, pp. 754-766, 2016.
M. Attal et al., "Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomized, multicentre, open-label, phase 3 study," The Lancet, vol. 394, no. 10214, pp. 2096-2107, 2019.
M.-V. Mateos et al., "Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma," New England Journal of Medicine, vol. 378, no. 6, pp. 518-528, 2018.
Downloads
Published
License
Copyright (c) 2024 University of Thi-Qar Journal of Science
This work is licensed under a Creative Commons Attribution 4.0 International License.
